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Non-malignantAbstract Introduction: Distinction between malignant and non-malignant pleural effusion is of
great importance in the patient management.
The aim: We examined the diagnostic value of C-reactive protein (CRP) and serum amyloid A
(SAA) in distinguishing different etiologies of pleural effusion and if they could discriminate
between malignant and non-malignant pleural effusions.
Subject and methods: CRP and SAA levels in both serum and pleural ﬂuid were measured in 92
patients with pleural effusion. Of the 92 patients included in our study; 44 were diagnosed with malig-
nant pleural effusions (group I) [withmale to female ratio (M/F) 23/21andmeanage 57.7 ± 11.5 years
in the form of mean ± 2SD] and 48 were diagnosed with non-malignant pleural effusion (group II)
[with M/F ratio 33/15 and mean age 54.7 ± 10.4 years in the form of mean ± 2SD].
Results: CRPandSAAvalueswere signiﬁcantly higher in both serumandpleural effusionofmalig-
nant vs. non-malignant group (P< 0.003), but therewas no statistical signiﬁcant difference as regards
pleural/serumCRP and pleural/serumSAA ratios between the two groups (P= 0.148 andP= 0.453
respectively). A statistically signiﬁcant positive correlationbetween pleural ﬂuidCRPandpleural ﬂuid
SAA in malignant and non-malignant effusions was detected (r= 0.315 and P= 0.002 respectively).
Diagnostic performance of pleural ﬂuid CRP and pleural ﬂuid SAA in both infectious and malignant
pleural effusions showed that at a cutoff value of 96.15 lg/ml for CRP; diagnostic sensitivity was 61%
and speciﬁcity was 45%,while for pleural ﬂuid SAA, a cutoff value of 137.5 lg/ml was associatedwith
41% sensitivity and 93% speciﬁcity.
Conclusion: Measurement of SAAandCRP levels in pleural ﬂuid has good diagnostic utility in dif-
ferentiationbetweenmalignant and non-malignant pleural effusion andpleural SAAhas a better diag-
nostic performance than CRP.
ª 2015 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Pleural effusion is an accumulation of ﬂuid in the pleural
space that exceeds the physiological amount of 10–20 ml.
Pleural effusion develops either when the formation of pleu-
ral ﬂuid is excessive and/or when the ﬂuid resorption is dis-
turbed [1].
Diagnosis and management of pleural effusion remain a
clinical challenge due to signiﬁcant cost both to patients and
to the health care system. In everyday clinical practice a variety
of laboratory tests are used for the differential diagnosis of
pleural effusions; however, a signiﬁcant proportion remains
undiagnosed [2].
A major problem remains the differentiation between
malignant and benign effusions, as they have different out-
come and management. Cytological examination of pleural
ﬂuid is a convenient and relatively efﬁcient method for estab-
lishing the diagnosis of pleural malignancy. However, pleural
ﬂuid cytology is positive in only 50% of cases [3]; therefore,
there is an increasing demand for markers that may help in this
differentiation.
Serum amyloid A (SAA) and C-reactive protein (CRP) are
acute-phase proteins predominantly produced and secreted by
hepatocytes [4]. Other cells including lymphocytes, monocytes,
and macrophages can also produce these proteins. The induc-
tion of SAA and CRP synthesis is triggered by a number of
cytokines, chieﬂy IL-6, which is released from a variety of cell
types, but mainly from macrophages and monocytes at inﬂam-
matory sites [4].
Increased serum CRP and SAA levels have been found in a
number of pulmonary disorders, including bacterial infections,
malignancies, and pulmonary thromboembolism. However,
only a few studies have focused on their role in pleural effu-
sions [5].Aim
The aim of this study was to assess the diagnostic value of C-
reactive protein (CRP) and serum amyloid A (SAA) in distin-
guishing different etiologies of pleural effusion and if they
could discriminate between malignant and non-malignant
pleural effusions.Patients and methods
Study subjects
We investigated 92 patients with pleural effusion. Patients were
divided into 2 groups:
Group I: (malignant pleural effusion), included 44
patients, [with male to female ratio (M/F)of 23/21 and a
mean age of 57.7 ± 11.5 years in the form of
mean ± 2SD].
Group II: (non- malignant or benign pleural effusion),
included 48 patients, [with M/F ratio 33/15 and a mean age
of 54.7 ± 10.4 years in the form of mean ± 2SD]. This group
included tuberculous, parapneumonic and transudative pleural
effusions.Study design
Patients were subjected to:
1. History taking.
2. Clinical examination.
3. Chest radiography.
4. Thoracic ultrasound.
5. Tuberculin skin test: using 5 units P.P.D in 0.1 ml intra-
dermal injection.
6. Laboratory investigations including: serum protein,
LDH, liver and kidney function tests.
7. Aspiration of pleural ﬂuid was done and was sent imme-
diately for the following:
a. Biochemical examination including: protein, LDH,
C-reactive protein and serum amyloid A (SAA)
levels.
b. Cytological examination.
c. Bacteriologic examination: Gram-staining, Ziehl–
Neelsen stain and culture.
8. Tissue biopsy: One of the following was done according
to case:
a. Abram’s needle pleural biopsy.
b. Thoracoscopic biopsy; if the closed pleural biopsy is
non diagnostic.
 Classiﬁcation of pleural ﬂuid into transudative or exudative
is based upon Light’s criteria (2002) [6]
 Transudative pleural effusion fulﬁlls the following criteria:
(1) Total ﬂuid protein is less than half of that of the total
serum protein level.
(2) Fluid Lactate Dehydrogenase (LDH) is less than 0.6
of that of the serum LDH.
(3) Pleural ﬂuid LDH is less than two thirds the upper
limit of the normal of that of the serum level.
 Effusions were considered malignant if malignant cells were
found on the cytology examination of pleural ﬂuid or in the
pleural biopsy specimens,
 The diagnosis of tuberculous pleurisy was based upon high
tuberculin positivity, lymphocytic pleural ﬂuid, few
mesothelial cells, elevated ADA level in the pleural ﬂuid
or pleural biopsy showing caseating granuloma.
 Criteria for parapneumonic effusion were; clinical, bio-
chemical and radiological signs of suspected pneumonia,
positive Gram staining, positive culture for bacteria or neu-
trophil predominance in pleural effusion.
Methods
*Serum and pleural SAA concentrations were determined
using Enzyme-linked immunosorbent assay (ELISA) kit sup-
plied by Assaypro (3400 Harry S Truman BlvdSt. Charles,
MO 63301USA).
*Serum and pleural CRP concentrations were determined
using ELISA kit supplied by ChemuxBioScience (South San
Francisco, CA 94080, USA).
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All statistical analyses were performed using the SPSS
(Statistical Package for Social Sciences) version 17.0 software.
Data were ﬁrst tested by Kolmogorov–Smimov test for distri-
bution of data. Data were expressed as mean and standard
deviation (SD) for numerical parametric data. The mean and
SD of the differences and the limits of agreement, deﬁned as
the mean ± 2 SD of the difference (95% CI), were calculated.
ANOVA test was used for intergroup comparisons of means,
A P-value of less than 0.05 indicated statistical signiﬁcance.
Correlations between numerical data were determined with
the Pearson’s rank correlation coefﬁcient. Analysis of receiver
operator characteristics (ROC) and calculation of the area
under the curve (AUC) were used for both CRP and SAA in
the pleural ﬂuid.
Results
Of the 92 patients included in our study; 44 were diagnosed
with malignant pleural effusion (group I) with male to female
ratio (M/F) 23/21and 48 were diagnosed with non-malignant
pleural effusion (group II) with an M/F ratio of 33/15. In
the malignant group the mean ± SD of the age wasTable 1 Etiology of pleural effusion and demographic data of
studied patients.
Etiology of pleural eﬀusion Number
of cases
Age
(Mean ± SD)
M/F
Malignant (group I):
(a) Lung cancer 6
(b) Mesothelioma 2
(c) Breast cancer 13
(d) Renal carcinoma 26
(e) Hepato-cellular carcinoma 6
(f) Non-Hodgkin lymphoma 2 57.7 ± 11.5 23/21
(g) Cancer colon 4
(h) Splenic cancer 2
(i) Thyroid carcinoma 3
(j) Cancer prostate 4
Non-malignant (group II):
(a) Tuberculous 12 51.3 ± 11 9/3
(b) Parapneumonic 19 55.6 ± 11 12/7
(c) Transudate: 17 56.2 ± 8.8 12/5
(liver- cell failure) (9)
(heart failure) (8)
Table 2 Serum and Pleural CRP and SAA values in the different s
Transudates (n= 17) Parapneumonic
(a) Pleural hs-CRP (lg/ml) 23 ± 24.9 103.9 ± 28
(b) Serum hs-CRP (lg/ml) 67.6 ± 43.5 138 ± 27
(c) Pleural/serum hs-CRP 0.3 ± 0.2 0.8 ± 0.2
(a) Pleural SAA (lg/ml) 2.9 ± 1.3 30.4 ± 17.3
(b) Serum SAA (lg/ml) 40.9 ± 14.8 128 ± 35
(c) Pleural/serum SAA 0.08 ± 0.04 0.2 ± 0.157.7 ± 11.5 years while in the non-malignant group it was
54.7 ± 10.4 years. Etiology of pleural effusion and demo-
graphic data of studied patients are presented in Table 1.
Levels of CRP and SAA in the pleural ﬂuid and serum of
the studied subjects are presented in Table 2 and Fig. 1.
There were statistically signiﬁcant differences regarding CRP,
SAA and pleural/serum ratio of both markers among the stud-
ied groups (P= 0.000).
When Post Hoc Test, Least Signiﬁcant Difference (LSD)
was performed; pleural CRP was signiﬁcantly higher in the
parapneumonic group than transudate and tuberculous groups
(P< 0.05), but no statistical signiﬁcant difference was found
between tuberculous and malignant groups (P= 0.08) or
malignant and parapneumonic groups (P= 0.25). Moreover;
pleural SAA values were signiﬁcantly higher in both tubercu-
lous andmalignant groups than transudate and parapneumonic
groups (P< 0.05), while there was no statistical signiﬁcant dif-
ference between tuberculous and malignant groups (P= 0.13).
CRP and SAA values were signiﬁcantly higher in both
serum and pleural effusion of malignant vs. non-malignant
group (P< 0.003) (Table 3), but there was no statistical
signiﬁcant difference as regards pleural/serum CRP andtudied groups.
(n= 19) Tuberculous (n= 12) Malignant (n= 44) P
72 ± 38 90.6 ± 34 0.000
116 ± 33 119 ± 27 0.000
0.6 ± 0.2 0.8 ± 0.3 0.000
93 ± 37 115 ± 60 0.000
206 ± 72 312 ± 114.4 0.000
0.5 ± 0.1 0.4 ± 0.2 0.000
Figure 1 Levels of CRP and SAA in pleural ﬂuid and serum of
the studied subjects.
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and P= 0.453 respectively).
The correlation analysis of pleural effusion for SAA, CRP
(Fig. 2) using Spearman’s test showed, in both malignant and
non-malignant effusions, a statistically signiﬁcant positive cor-
relation between pleural ﬂuid CRP and SAA (r= 0.315 and
P= 0.002).
Receiver Operating Characteristic (ROC) curve for pleural
ﬂuid CRP and SAA in both infectious (including parapneu-
monic and tuberculous pleural effusions) and malignant pleu-
ral effusions was plotted Fig. 3.
Assessment of the diagnostic performance of pleural ﬂuid
CRP in both infectious and malignant effusions showed that
at a cutoff value of 96.15 lg/ml for CRP; diagnostic sensitivity
was 61% and speciﬁcity was 45%, while for pleural ﬂuid SAA,
a cutoff value of 137.5 lg/ml was associated with 41% sensitiv-
ity and 93% speciﬁcity. ROC curve shows that the AUC was
higher for pleural ﬂuid SAA than CRP (0.796 and 0.479,
respectively).Table 3 Serum and pleural CRP and SAA values in malig-
nant and nonmalignant cases.
Non-malignant
(n= 48)
Malignant
(n= 44)
P
Pleural CRP (lg/ml) 67.3 ± 46 90.6 ± 34 0.000
Serum CRP (lg/ml) 107.5 ± 46.4 119 ± 27 0.002
Pleural/serum CRP ±0.3 0.8 ± 0.3 0.148
Pleural SAA (lg/ml) 36.2 ± 41 115 ± 60 0.001
Serum SAA (lg/ml) 116.8 ± 77 312 ± 114.4 0.003
Pleural/serum SAA ±0.2 0.4 ± 0.2 0.453
Figure 2 Correlation between pleural ﬂuid CRP andDiscussion
Pleural effusion (PE) is often a clinical problem in medical
practice, as the differential diagnosis includes a wide variety
of local and systemic diseases. Considerable effort has
been made to develop a simple, inexpensive and noninvasiveSAA in malignant and non-malignant effusions.
Figure 3 (ROC) curve for pleural ﬂuid CRP and SAA in both
infectious and malignant pleural effusions.
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and clinical settings. No standard biochemical approach has
yet been established. Ideal biomarkers should be easily mea-
sured at a reasonable cost (analytical validity), sensitive and
speciﬁc to the disease state being examined, and aid in
decision-making (clinical usefulness) [7].
SAA and CRP are acute-phase proteins predominantly
produced and secreted by hepatocytes [4]. Although several
studies have investigated the serum levels of the acute-phase
proteins CRP and SAA in diseases, few have focused on the
levels of these types of proteins in effusions.
Vidriales and Antaquera [8], Turay et al. [9], Tatjana et al.
[10] found that pleural ﬂuid CRP levels were highly elevated in
parapneumonic effusion, than in other types of effusion.
Tatjana et al. [10] also found that there is no signiﬁcant dif-
ference between malignant and tuberculous effusions as regards
pleural ﬂuid CRP levels. Our study showed similar results; pleu-
ral ﬂuid CRP was signiﬁcantly higher in the parapneumonic
group than transudate and tuberculous groups (P< 0.05),
but no statistically signiﬁcant difference was detected between
tuberculous and malignant groups (P= 0.08) or malignant
and parapneumonic groups (P= 0.25). On the contrary,
Chierakul et al. [11] and Garcia Patchon et al. [12] found that
pleural ﬂuid CRP levels were twice as high in tuberculous than
in malignant effusion, while Turay et al. [9] found higher CRP
effusion value in malignant effusion.
In agreement of our results, Hoda Abu-Youssef et al. [13]
reported that there was a statistically highly signiﬁcant differ-
ence for mean values of CRP between transudative and exuda-
tive pleural ﬂuid effusions (P< 0.003) with higher levels in
exudative effusion than those of transudative effusion.
An additional ﬁnding of our study is that pleural ﬂuid CRP
levels were higher in parapneumonic compared to tuberculous
and malignant effusions. This may be attributed to the fact
that CRP plays an important role in inﬂammation, as it
increases profoundly in the region of inﬂammation [4].
Our study revealed that, pleural SAA values were signiﬁ-
cantly higher in both tuberculous and malignant groups than
transudate and parapneumonic groups (P< 0.05), while there
was no statistically signiﬁcant difference between tuberculous
and malignant groups (P= 0.13).
Our study demonstrated a statistically signiﬁcant positive
correlation between pleural ﬂuid CRP and SAA in malignant
and non- malignant effusions. In a research done by
Alesssandra et al. [14] correlation analysis of serum and effu-
sion SAA and CRP, showed a stronger correlation for SAA
than for CRP in exudates and although SAA and CRP were
highly correlated in the serum, they were only slightly corre-
lated in exudates.
Assessment of the diagnostic performance of pleural ﬂuid
CRP and pleural ﬂuid SAA in both infectious (including para-
pneumonic and tuberculous pleural effusions) and malignant
pleural effusions showed that at a cutoff value of 96.15 lg/ml
for CRP; diagnostic sensitivity was 61% and speciﬁcity was
45%, while for pleural ﬂuid SAA, a cutoff value of 137.5 lg/ml
was associated with 41% sensitivity and 93% speciﬁcity. ROC
curve shows that the AUC was higher for pleural ﬂuid SAA
than CRP (0.796 and 0.479, respectively). A previous study
done by Kiropoulos et al. [15] found that pleural ﬂuid CRP
was higher in parapneumonic compared to tuberculous and
malignant effusions, providing 100% sensitivity and 79%
speciﬁcity using a cut-off point of 5.3 mg/dL.The study of Rezaeetalab and his colleagues [16] reported
that in discrimination between the exudates and transudates,
a cutoff value of 5 mg/L for pleural ﬂuid CRP showed 94%
sensitivity and 96.6% speciﬁcity.
In summary, in this prospective study of acute phase mark-
ers in pleural effusions of different etiologies; we reported that
at a cutoff value of 96.15 lg/ml for CRP; and 137.5 lg/ml for
SAA in pleural ﬂuid; these two markers may have diagnostic
utility for the differentiation of infectious (parapneumonic
and tuberculous) effusion from malignant effusions and pleu-
ral SAA has a better diagnostic performance than CRP.
CRP and SAA determinations are relatively simple, rapid,
and inexpensive and in this study we ﬁnd that they may con-
tribute to this discrimination.
Conclusion
Measurement of SAA and CRP levels in pleural ﬂuid has a
good diagnostic utility in differentiation between malignant
and non-malignant pleural effusion and pleural SAA has a bet-
ter diagnostic performance than CRP.Conﬂict of interests
The authors declare that there is no conﬂict of interests.
References
[1] R.W. Light, Etiology of Pleural Effusion, Pleural Diseases, 4th
ed., Lippincott Williams and Wilkins, Philadelphia, 2001, pp.
86–95.
[2] M. Marel, B. Stastny, L. Melinova, et al, Diagnosis of pleural
effusions. Experience with clinical studies, 1986 to 1990, Chest
107 (1995) 1598–1603 [SD-008].
[3] J.M. Porcel, Pearls and myths in pleural ﬂuid analysis,
Respirology 16 (2011) 44–52, View Article: Google Scholar:
PubMed/NCBI.
[4] C. Gabay, I. Kushner, Acute-phase proteins and other systemic
responses to inﬂammation, N. Engl. J. Med. 340 (1999) 448–454.
[5] A.M. Okino, C. Bu¨rger, J.R. Cardoso, E.L. Lavado, P.A.
Lotufo, A. Campa, The acute-phase proteins serum amyloid A
and C reactive protein in transudates and exudates, Mediators
Inﬂamm (2006). Article ID 47297.
[6] R.W. Light, Clinical practice. Pleural effusion, N. Engl. J. Med.
346 (25) (2002) 1971–1977.
[7] J.M. Porcel, Pleural ﬂuid biomarkers: beyond the light criteria,
Clin. Chest Med. 34 (2013) 27–37, View Article: Google Scholar:
PubMed/NCBI.
[8] J.L. Vidriales, A.C. Antaquera, Use of C reactive protein in
laboratory diagnosis of pleural effusions, Eur. J. Med. 1 (1992)
201–207.
[9] Y.U. Turay, Z. Yildirim, Y. Turkoz, C. Biber, Y. Erdogan, A.I.
Keyf, F. Ugurman, A. Ayaz, P. Ergun, M. Harputluoglu, Use of
pleural ﬂuid C-reactive protein in diagnosis of pleural effusions,
Respir. Med. 94 (5) (2000) 432–435.
[10] R.P. Tatjana, P. Tatjana, S. Vojin, V. Predrag, R. Danijela, N.B.
Desa, Use of C-reactive protein in pleural ﬂuid for differential
diagnosis of benign and malignant effusion, Acta Fac. Med.
Naiss. 24 (2) (2007) 89–93.
[11] N. Chierakul, A. Kanitsap, R. Viriataveekul, Simple C-reactive
protein measurement for the differentiation between tuberculous
and malignant pleural effusion, Respirology 9 (2004) 66–69.
[12] E. Garcia-Patchon, M.J. Soler, I. Padilla-Navas, V. Romero, C.
Shum, C-reactive protein in lymphocytic pleural effusions: A
892 H.M.S. Samaha et al.diagnostic aid in tuberculous pleuritis, Respiration 72 (2005)
486–489.
[13] Hoda Abu-Youssef, Sherif Amin, Hassan Amin, Essam Osman,
Value of C-reactive protein in etiologic diagnosis of pleural
effusion, EJB 4 (2) (2010) 127–130.
[14] M.O. Alesssandra, B. Cristiani, R.C. Jefferson, L.L. Edson,
A.L. Paulo, C. Ana, The acute-phase proteins serum amyloid A
and C reactive protein in transudates and exudates, Mediators
Inﬂamm. 2006 (1) (2006) 472–497.[15] T.S. Kiropoulos, K. Kostikas, S. Oikomonidi, I. Tsilionia, D.
Nikoulisb, A. Germenisb, K.I. Gourgoulianisa, Acute phase
markers for the differentiation of infectious and malignant
pleural effusion, Respir. Med. 101 (2007) 910–918.
[16] F. Rezaeetalab, S.M. Parizadeh, H. Esmaeely, F. Akbari, S.
Saberi, Tumor necrosis factor alpha and high sensitivity
creactive protein in diagnosis of exudative pleural effusion, J.
Res. Med. Sci. 16 (11) (2011) 1405–1409.
